Pathologic observations in human allograft recipients treated with FK 506.

摘要: FK 506, a powerful new immunosuppressant, has proved to be an effective drug for the prevention and treatment of allograft rejection in animals.1–8 In some respects, it was even shown superior CyA, which revolutionized solid organ transplantation decade earlier. However, during trials experimental animals, serious questions were raised regarding its potential toxicity. Wide-spread arterial necrosis, induction diabetic state, renal tubular liver damage among most worrisome harmful effects attributed this agent.9–12 These reported toxicities varied with animal species used. Rats could given relatively large doses seemingly little consequence,13 while dogs same amounts on per weight basis experienced vomiting emaciation, often died.6 Evidence peculiar, noninflammatory necrosis media periadventitia muscular arteries found at time death canine subjects.6,8,9–12 Nevertheless, our group6,8 Ochiai et al14 noted lesions animals who never received drug, other side not observed all.6,8,13 findings eased some, but all, concern surrounding use 506 humans. Encouraged by promise agent inconclusive nature effects, clinical cautiously undertaken humans had already allografts, whose organs failing from under conventional therapy, CyA mainstay immunosuppressant. fact, many these first patients lost one or more grafts rejection. The following report is account pathologic allografts tissues drug.